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Introduction
Triptans are highly selective agonists of the 5-HT1B/1D sero-
tonergic receptors and they have revolutionised the treat-
ment of migraine in the past decade. Commonly used trip-
tans include sumatriptan, zolmitriptan, eletriptan, rizatriptan
and naratriptan. All these agents seem to have similar clini-
cal efficacy and safety profiles. In view of their selective
affinity for 5-HT1B/1D receptors, they are usually well toler-
ated and have few adverse effects. A few authors have
reported myocardial ischaemia and stroke in association
with triptan use [1, 2] and there is an isolated report of spon-
taneous splenic infarction following use of zolmitriptan [3].
We report a patient who developed a spontaneous infarction
of the spleen after treatment with sumatriptan.
Case report
A 52-year-old female with a history of migraine
headaches and depression presented to the hospital with
sudden onset, sharp, left-sided chest pain located just
below the breast. She denied any fever, cough, dyspnoea,
abdominal pain, trauma, recent surgery, travel or oral con-
traceptive use. Her headaches began at the age of 17 years
and were usually unilateral, throbbing in nature and were
associated with nausea, vomiting and photophobia. They
used to last for a day or two and were treated with ibupro-
fen. These episodes were not accompanied by preceding
aura, sensory or visual symptoms. Frequency of the
headaches was 1–2 times/month and she had never been
on any preventive therapy. She had been using sumatrip-
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Abstract Triptans are specific ago-
nists of the serotonergic 5-HT1B/1D
receptors that have increasingly
been used in the treatment of
migraine and cluster headaches.
Though they are generally consid-
ered safe, there have been a few
reports of myocardial infarction and
stroke associated with triptan use.
We report a patient who developed
spontaneous splenic infarction after
the use of sumatriptan for the treat-
ment of migraine headache.
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tan 50 mg for acute therapy for the last 4–5 years. A few
weeks prior to hospitalisation, the frequency of her
migraines increased (1–2 episodes/week), which she
attributed to work-related stress. She had consumed 2
tablets of sumatriptan (50 mg) on 3 occasions in the week
prior to hospitalisation with the last dose being around 6 h
before the onset of symptoms. She had been diagnosed
with depression 2 years previously when she started hav-
ing symptoms of anhedonia, lack of energy, decreased
appetite and sleep disturbances and had been taking esci-
talopram 10 mg/day for the last 18 months. She was a
chronic smoker and denied any family history of hyperco-
agulable state, stroke or heart disease.
Physical examination was unremarkable except for
mild left upper quadrant tenderness without
splenomegaly. Laboratory investigations including com-
plete blood counts with peripheral smear, coagulation
studies, basic metabolic panel, liver and thyroid function
tests were within normal limits. EKG, chest X-ray and
cardiac enzymes were normal. D-dimer was mildly ele-
vated at 0.83 ng/l (0–0.5 ng/l). CT scan of chest and
abdomen was negative for pulmonary embolism and
showed a wedge-shaped opacity in the spleen suggestive
of acute infarction (Fig. 1). Screening tests for connective
tissue disorders and hypercoagulable states including anti-
nuclear antibody, antineutrophil cytoplasmic antibodies
(ANCA), rheumatoid factor, complement levels, antiphos-
pholipid antibodies, factor V Leiden and prothrombin
mutations, protein C and S, antithrombin III deficiencies
and hyperhomocysteinaemia were negative. Haemoglobin
electrophoresis, 2D echocardiogram and venous Dopplers
were unremarkable. Her symptoms gradually improved
with non-steroidal anti-inflammatory medications. She
was discharged home in a stable condition with the advice
to avoid triptans and ergotamines.
Discussion
Splenic infarction is usually encountered in association
with haematological diseases, thromboembolic states and
vasculitides, especially systemic lupus erythematosus with
lupus anticoagulant or antiphospholipid antibodies [4].
Splenic infarction has also been known to occur in patients
with moderate to severe splenomegaly, falciparum malar-
ia, sickle cell disease, rupture of splenic artery aneurysm,
Kawasaki’s disease, Wegener’s granulomatosis and in
patients with cocaine abuse. We describe here a patient
who developed spontaneous splenic infarction after suma-
triptan use. Though it is difficult to establish a causal rela-
tionship, there are certain features that suggest possible
association of splenic infarct with sumatriptan use. First,
there was a clear and close temporal association between
ingestion of the drug and development of symptoms.
Second, extensive work-up failed to reveal an alternate
cause such as haematological malignancy, hypercoagula-
ble state or any atherothrombotic risk factors. Finally, trip-
tans may potentially cause vasoconstriction in extra-cere-
bral sites, which could have a role to play in the develop-
ment of splenic infarction in our patient.
5HT1B receptors are present in abundance on vascular
endothelium and meningeal vessels and mediate triptan-
induced contraction of vascular smooth muscle [5].
Triptans help in relieving migraine headache and associat-
ed symptoms by causing selective constriction of pain-
producing intracranial extra-cerebral blood vessels,
decreasing trigeminal sensory nerve activation and inhibi-
tion of vasoactive neuropeptide release. Vasoactive pep-
tides found in the trigeminal neurons that innervate
intracranial blood vessels include calcitonin gene-related
peptide (CGRP), substance P and neurokinin A. Both
CGRP and substance P have endothelium-dependent
vasodilatory actions on the cerebral vasculature [6]. Other
possible mechanisms of triptans include modulation of
nitric oxide (NO)-dependent signal transduction path-
ways, NO scavenging and modulation of sodium-depen-
dent cell metabolic activity [7]. This is based on the
assumption that NO may have a role in production of
migraine headaches as administration of nitroglycerine in
patients with underlying migraine can cause dose-depen-
dent migraine-like headaches [7].
The optimum dose of triptans for migraine headaches
is not clearly defined. Results from a clinical trial of
sumatriptan have shown that an initial dose of 50 mg is as
Fig. 1 Contrast-enhanced CT scan of abdomen showing wedge-
shaped splenic infarct (arrow)
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effective as 100 mg and may have lesser incidence of
adverse reactions [8]. It is recommended that total dose of
sumatriptan should not exceed 200 mg/day. Triptans are
usually well tolerated but occasionally may cause fatigue,
dizziness, a “warm” sensation after subcutaneous injec-
tion and “tightness” in the throat and chest. The major
concern with the use of triptans has been the potential for
vasoconstriction, especially of the coronary and intracere-
bral vessels. There are a few case reports of patients
developing cardiovascular complications including
myocardial infarction, arrhythmias and strokes secondary
to use of triptans [1, 2]. Isolated cases of mesenteric
infarction [9] and a case of spinal cord infarction have
also been reported [10]. In one study, invasive haemody-
namic monitoring in ten patients undergoing coronary
angiogram revealed that subcutaneous injection of suma-
triptan caused significant increase in systemic and pul-
monary artery pressures and a significant reduction in
mean coronary artery diameter [11]. In view of these con-
cerns, triptans are contraindicated in patients with estab-
lished cardiac and cerebrovascular disease.
The probable pathogenic mechanisms responsible for
splenic infarction with triptan use in our patient include
splenic ischaemia secondary to vasospasm of the splenic
artery either by a direct effect on vascular smooth muscles
and/or inhibition of release of vasoactive peptides. Our
hypothesis is supported by previous observations of
development of mesenteric ischaemia and ischaemic coli-
tis with triptan use. A case similar to our patient with
spontaneous splenic infarction following the use of
zolmitriptan has also been described [3]. Though not
reported in the literature, it is possible that splenic and
mesenteric vasculature may also have 5HT1B/1D receptors,
as seen in meningeal vessels, resulting in triptan-induced
vasoconstriction and ischaemia.
Conclusions
In conclusion, our case emphasises the need to recognise
the possible association of triptans with intra-abdominal
ischaemic complications. As triptans are the mainstay of
acute management of migraine headaches, they should be
used judiciously, especially in patients with a risk of
atherothrombotic diseases and hypercoagulable states.
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